<p>Cassava Sciences（纳斯达克代码：SAVA - 获取免费报告）预计将在 2025 年 3 月 3 日星期二市场开盘前发布其 2025 年第四季度财报。分析师预计 Cassava Sciences 本季度每股收益为（$0.30）。投资者可以查看公司即将发布的 2025 年第四季度财报摘要页面，以获取关于定于 2026 年 3 月 10 日上午 10:30（东部时间）的电话会议的最新详情。</p>
<p>获取 <strong>Cassava Sciences</strong> 警报：</p>
<h2>Cassava Sciences 股票下跌 3.0%</h2>
<ul>
<li>分析师认为 Cassava Sciences 现在有 300% 的上涨空间</li>
</ul>
<p>纳斯达克 SAVA 周一开盘价为 $2.28。Cassava Sciences 的 52 周低点为 $1.15，52 周高点为 $4.98。该股票的市值为 $1.1015 亿，市盈率为 -1.04，贝塔值为 -0.85。该公司的 50 日移动平均线为 $2.12，200 日移动平均线为 $2.68。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司最近对 SAVA 发布了报告。Weiss Ratings 在 12 月 26 日星期五的研究报告中重申了对 Cassava Sciences 股票的 “卖出（e+）” 评级。Wall Street Zen 在周六的研究报告中将 Cassava Sciences 的评级从 “持有” 下调至 “卖出”。一位分析师对该股票给予了 “持有” 评级，另一位分析师则给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “减持”，平均目标价为 $2.00。</p>
<ul>
<li>Cassava Sciences：一个值得交易、投资或避免的热门股票？</li>
</ul>
<p><strong>查看我们关于 Cassava Sciences 的最新研究报告</strong></p>
<h2>对 Cassava Sciences 的对冲基金看法</h2>
<p>几家大型投资者最近买入和卖出了该股票的股份。Jump Financial LLC 在第四季度收购了价值约 $181,000 的 Cassava Sciences 新股份。Federated Hermes Inc.在第四季度将其在 Cassava Sciences 的持股增加了 111.3%。Federated Hermes Inc.目前拥有 91,479 股该公司的股票，价值 $181,000，在此期间又购买了 48,194 股。Strs Ohio 在第一季度购买了价值约 $178,000 的 Cassava Sciences 新股份。OMERS ADMINISTRATION Corp 在第四季度购买了价值约 $166,000 的 Cassava Sciences 新股份。最后，Marshall Wace LLP 在第二季度收购了价值约 $130,000 的 Cassava Sciences 新股份。机构投资者和对冲基金持有该公司 38.05% 的股票。</p>
<h2>关于 Cassava Sciences</h2>
<p>（获取免费报告）</p>
<ul>
<li>3 家小型生物科技公司在 2024 年有潜在突破</li>
</ul>
<p>Cassava Sciences, Inc 是一家临床阶段的生物制药公司，专注于开发针对阿尔茨海默病及相关神经退行性疾病的新疗法和诊断工具。公司总部位于德克萨斯州奥斯汀，最初于 1998 年成立为 Pain Therapeutics，并于 2017 年更名为 Cassava Sciences。Cassava 的研究项目集中在旨在解决神经退行性疾病的潜在机制的小分子药物，而不仅仅是针对淀粉样斑块或 tau 缠结。</p>
<p>该公司的主要药物候选者 simufilam（前称 PTI-125）是一种专有小分子，旨在恢复支架蛋白 filamin A 的正常形状和功能，该蛋白与阿尔茨海默病患者的神经信号传导受损和炎症有关。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Cassava Sciences</li>
<li>白银突破 $100：下一个 $500 的飙升会来吗？（加入我们 3 月 4 日）</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>ATCX 坐拥巴西最大的关键矿产组合之一！</li>
<li>美国的 1776 再次发生</li>
<li>我 70 岁，拥有 150 万美元：将每年 12 万美元转换为罗斯账户是否明智，还是代价高昂的错误？（咨询顾问）</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FWQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FWQQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Cassava Sciences 吗？</h2>
<p>在考虑 Cassava Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Cassava Sciences 并不在名单上。</p>
<p>虽然 Cassava Sciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SAVA

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Cassava Sciences（纳斯达克代码：SAVA）将于 3 月 3 日公布 2025 年第四季度财报，分析师预测每股亏损 0.30 美元。该股目前下跌 3.0%，交易价格为 2.28 美元，市值为 1.1015 亿美元。最近的分析师评级包括来自 Weiss Ratings 的 “卖出” 评级和 Wall Street Zen 的下调评级。机构投资者持有该股票的 38.05%。Cassava 专注于开发阿尔茨海默病的治疗方案，其主要候选药物 simufilam 针对神经退行性机制</p>

<p>Cassava Sciences (NASDAQ:SAVA - Get Free Report) is expected to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Cassava Sciences to post earnings of ($0.30) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 10:30 AM ET.</p>
<div class="lb-trans"><p>Cassava Sciences（纳斯达克代码：SAVA - 获取免费报告）预计将在 2025 年 3 月 3 日星期二市场开盘前发布其 2025 年第四季度财报。分析师预计 Cassava Sciences 本季度每股收益为（$0.30）。投资者可以查看公司即将发布的 2025 年第四季度财报摘要页面，以获取关于定于 2026 年 3 月 10 日上午 10:30（东部时间）的电话会议的最新详情。</p>
</div><p>Get <strong>Cassava Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cassava Sciences</strong> 警报：</p>
</div><h2>Cassava Sciences Stock Down 3.0%</h2>
<div class="lb-trans"><h2>Cassava Sciences 股票下跌 3.0%</h2>
</div><ul>
<li>Analysts Believe Cassava Sciences Now Has 300% Upside From Here</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为 Cassava Sciences 现在有 300% 的上涨空间</li>
</ul>
</div><p>NASDAQ SAVA opened at $2.28 on Monday. Cassava Sciences has a 52 week low of $1.15 and a 52 week high of $4.98. The stock has a market capitalization of $110.15 million, a PE ratio of -1.04 and a beta of -0.85. The firm has a 50 day moving average of $2.12 and a two-hundred day moving average of $2.68.</p>
<div class="lb-trans"><p>纳斯达克 SAVA 周一开盘价为 $2.28。Cassava Sciences 的 52 周低点为 $1.15，52 周高点为 $4.98。该股票的市值为 $1.1015 亿，市盈率为 -1.04，贝塔值为 -0.85。该公司的 50 日移动平均线为 $2.12，200 日移动平均线为 $2.68。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms have recently issued reports on SAVA. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Cassava Sciences in a research report on Friday, December 26th. Wall Street Zen cut Cassava Sciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Reduce&#34; and an average target price of $2.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 SAVA 发布了报告。Weiss Ratings 在 12 月 26 日星期五的研究报告中重申了对 Cassava Sciences 股票的 “卖出（e+）” 评级。Wall Street Zen 在周六的研究报告中将 Cassava Sciences 的评级从 “持有” 下调至 “卖出”。一位分析师对该股票给予了 “持有” 评级，另一位分析师则给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “减持”，平均目标价为 $2.00。</p>
</div><ul>
<li>Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?</li>
</ul>
<div class="lb-trans"><ul>
<li>Cassava Sciences：一个值得交易、投资或避免的热门股票？</li>
</ul>
</div><p><strong>View Our Latest Research Report on Cassava Sciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Cassava Sciences 的最新研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On Cassava Sciences</h2>
<div class="lb-trans"><h2>对 Cassava Sciences 的对冲基金看法</h2>
</div><p>Several large investors have recently bought and sold shares of the stock. Jump Financial LLC acquired a new stake in shares of Cassava Sciences in the 4th quarter valued at about $181,000. Federated Hermes Inc. increased its position in Cassava Sciences by 111.3% during the fourth quarter. Federated Hermes Inc. now owns 91,479 shares of the company's stock worth $181,000 after buying an additional 48,194 shares during the period. Strs Ohio purchased a new stake in Cassava Sciences in the first quarter valued at approximately $178,000. OMERS ADMINISTRATION Corp purchased a new stake in Cassava Sciences in the fourth quarter valued at approximately $166,000. Finally, Marshall Wace LLP acquired a new stake in shares of Cassava Sciences in the second quarter valued at approximately $130,000. Institutional investors and hedge funds own 38.05% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了该股票的股份。Jump Financial LLC 在第四季度收购了价值约 $181,000 的 Cassava Sciences 新股份。Federated Hermes Inc.在第四季度将其在 Cassava Sciences 的持股增加了 111.3%。Federated Hermes Inc.目前拥有 91,479 股该公司的股票，价值 $181,000，在此期间又购买了 48,194 股。Strs Ohio 在第一季度购买了价值约 $178,000 的 Cassava Sciences 新股份。OMERS ADMINISTRATION Corp 在第四季度购买了价值约 $166,000 的 Cassava Sciences 新股份。最后，Marshall Wace LLP 在第二季度收购了价值约 $130,000 的 Cassava Sciences 新股份。机构投资者和对冲基金持有该公司 38.05% 的股票。</p>
</div><h2>About Cassava Sciences</h2>
<div class="lb-trans"><h2>关于 Cassava Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>3 small-cap biotechs with potential breakthroughs in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家小型生物科技公司在 2024 年有潜在突破</li>
</ul>
</div><p>Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer's disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava's research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles.</p>
<div class="lb-trans"><p>Cassava Sciences, Inc 是一家临床阶段的生物制药公司，专注于开发针对阿尔茨海默病及相关神经退行性疾病的新疗法和诊断工具。公司总部位于德克萨斯州奥斯汀，最初于 1998 年成立为 Pain Therapeutics，并于 2017 年更名为 Cassava Sciences。Cassava 的研究项目集中在旨在解决神经退行性疾病的潜在机制的小分子药物，而不仅仅是针对淀粉样斑块或 tau 缠结。</p>
</div><p>The company's lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer's patients.</p>
<div class="lb-trans"><p>该公司的主要药物候选者 simufilam（前称 PTI-125）是一种专有小分子，旨在恢复支架蛋白 filamin A 的正常形状和功能，该蛋白与阿尔茨海默病患者的神经信号传导受损和炎症有关。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cassava Sciences</li>
<li>Silver Crossed $100: Is the $500 surge next? (Join us March 4)</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>ATCX is Sitting on One of Brazil’s Largest Critical Minerals Portfolios!</li>
<li>America’s 1776 happening again</li>
<li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Cassava Sciences</li>
<li>白银突破 $100：下一个 $500 的飙升会来吗？（加入我们 3 月 4 日）</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>ATCX 坐拥巴西最大的关键矿产组合之一！</li>
<li>美国的 1776 再次发生</li>
<li>我 70 岁，拥有 150 万美元：将每年 12 万美元转换为罗斯账户是否明智，还是代价高昂的错误？（咨询顾问）</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FWQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SAVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cassava Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Cassava Sciences 吗？</h2>
</div><p>Before you consider Cassava Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cassava Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Cassava Sciences 并不在名单上。</p>
</div><p>While Cassava Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cassava Sciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cassava Sciences (SAVA) 预计将在周二宣布季度财报